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Abstract. Aim: This study aimed at exploring several brain
metastatic prognostic scores in patients with renal cell
carcinoma. Patients and Methods: We retrospectively analyzed
data of 93 metastatic renal cell carcinoma patients who were
diagnosed with brain metastases between October 2005 and July
2016 who received targeted therapy. Potential prognostic factors
(RTOG RPA, BS-BM, and a newly developed score CERENAL)
were analyzed. Results: A total of 75 patients received targeted
therapy. All scores showed prognostic value in progression-free
survival after first-line treatment with CERENAL being the sole
independent prognostic factor associated with improved duration
of first-line treatment. Both RTOG RPA and CERENAL were
potential prognosticators for overall survival, whereas only the
CERENAL score was associated with prolonged disease-specific
survival. Conclusion: Several prognostic scores can be useful to
predict survival of patients with brain metastases from renal
cancer, especially the newly developed CERENAL score.
Renal cell carcinoma (RCC) accounts for 2.4% of all
malignancies diagnosed worldwide with 337,800 estimated
new cases globally and 115,200 new patients in Europe in
2012 (1-3). At primary diagnosis, approximately 25% of
patients are diagnosed with advanced RCC (4). 
In case of metastatic disease, median overall survival (OS)
is 18.8 months, with 5-year disease-specific survival rates of
32%, 19.5% and 0% found for patients with low-,
intermediate- and high-risk respectively (1, 5). However,
recent data from trials with immunotherapy in metastatic
RCC showed 2-year OS rates up to 70% (5).
Brain metastases occur in 10% of metastatic RCC patients
(6). Local treatment options such as surgery or radiotherapy
are considered the standard of care to treat brain metastases.
However, as brain metastases tend to be relatively resistant to
whole-brain radiation therapy, use of stereotactic radiosurgery
seems to result in a satisfactory control of brain metastases
with only a limited survival benefit (7, 8). Nevertheless,
overall prognosis remains poor with nearly all patients
succumbing to the disease within 2 years of brain metastasis
diagnosis (8, 9).
Several prognostic scores for brain metastases have been
reported to determine the prognostic outcome of patients
following brain surgery or radiotherapy, such as the
Radiation Therapy Oncology Group Recursive Partitioning
Analysis (RTOG RPA), the Score Index for Radiosurgery
and the Basic Score for Brain Metastases (BS-BM) (10-12).
However, these scores were developed and validated in
studies with various tumor types, usually with none or only
one small RCC subgroup.
Therefore, the goal of this retrospective study was to
validate the brain metastasis prognostic scores RTOG-RPA
and BS-BM in patients with renal cell cancer treated with
targeted therapies. Next, we aimed at developing a potential
new tool named CERENAL score for this population and
evaluate the prognostic potential for PFS and OS.
Patients and Methods
Patient selection. We retrospectively identified metastatic RCC
patients who were diagnosed with or developed brain metastases
during the course of their disease in four international cancer centers
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between October 2005 and July 2016. Patient data were retrieved
from the electronic patient files. All patients with brain metastases
treated with targeted therapies, including tyrosine kinase inhibitors
and mTOR inhibitors, were included. This study was approved by
the Ethics Committee of all participating centers. Informed consent
was given by all participants. The study was conducted according
to the principles of the Helsinki declaration.
Prognostic factors. Brain metastasis prognostic scores were
determined as described in literature. Patients were distributed
among RTOG RPA classes I, II or III using age, Karnofsky
performance status (KPS) and presence of extracranial metastases
at brain metastasis diagnosis (10). Next, the BS-BM was determined
using KPS, management of systemic disease and presence of
extracranial metastases at brain metastasis diagnosis. Up to one
point was attributed per prognostic factor with a final BS-BM
ranging between 0 and 3 (11). Due to limited data in the patient data
files on the volume of the brain lesions, the Score Index for
Radiosurgery (12) could not be calculated.
As the majority of these scores were developed and validated in
populations with mainly lung cancer, breast cancer, or malignant
melanoma, a novel brain metastasis prognostic score was devised,
namely CERENAL, based on the prognostic parameters used for the
RTOG RPA and the BS-BM and findings in literature showing that
a low number of intracranial metastases and SRS may predict a
substantial survival benefit for metastatic RCC patients (8, 13). In
this score, 1 point was attributed for each negative prognostic factor
for a total score ranging between 0 and 6 points. All three brain
metastasis prognostic scores are described in Table I. All prognostic
scores were then dichotomized for survival analysis based on
median numbers for each prognostic variable. Patients were
subdivided as RTOG RPA class I-II versus RTOG RPA class III. For
BS-BM and CERENAL, cut-off was taken at ≤2 and ≤4,
respectively. Insufficient retrospective data was available to
determine MSKCC or Heng criteria.
Statistical analysis. Spearman’s rank correlation coefficient ρ was
assessed between prognostic scores. The overall percentage
agreement was calculated pairwise for comparison between all
dichotomized prognostic scores. Each prognostic score was
calibrated for progression-free survival (PFS, time from treatment
initiation until radiographic progression or discontinuation due to
adverse events) and OS (time from brain metastasis diagnosis until
day of death or last follow-up) by means of a logistic regression
model (Hosmer-Lemeshow test). Small χ2/larger p-values indicate
a good model fit.
The hazard ratio (HR) of each prognostic score on first-line PFS,
second-line PFS, OS and disease-specific survival (DSS) was
determined by a 2-sided log-rank (Mantel–Cox) test. Patients that
were lost to follow-up were censored in the survival analysis.
Survival curves were plotted using the Kaplan–Meier method.
Comparison of survival rates between all dichotomized prognostic
scores for six-months first-line PFS, six-months second-line PFS,
six-months OS, one-year OS, six-months DSS, and one-year DSS
was performed using decision curve analysis (14). The covariate
effect of the survival risk factors (reaching p-value <0.05 on
univariate test), was determined via Cox proportional hazard model
(backward method). Missing values were not included in the
analyses. p-Values<0.05 were considered statistically significant.
Analyses were performed with MedCalc Statistical Software v17.4
(MedCalc Software, Ostend, Belgium); SPSS v23.0 (IBM
corporation, Armonk, NY, USA), GraphPad Prism v4.7 (GraphPad
Software Inc., La Jolla, CA, USA) and RStudio v3.5.1 (RStudio,
Boston, MA, USA).
Results
Patient characteristics and prognostic scores. Out of 93 RCC
patients who were diagnosed with brain metastasis, eighteen
patients did not receive targeted therapy and were excluded
from all analyses. An overview of the clinical characteristics
as well as a descriptive analysis concerning the diagnosis and
specific treatment of brain metastases in the intention-to-treat
cohort (75 cases) is given in Tables II and III, respectively.
Patient distribution among brain metastasis prognostic scores
is shown in Table IV. Prognostic scores were comparable to
each other. A moderate rank correlation was found between
RTOG RPA and BS-BM (ρ=–0.700, p<0.0001) and between
CERENAL and BS-BM (ρ=–0.702, p<0.0001) whereas a fair
rank correlation was found between RTOG RPA and
CERENAL (ρ=0.533, p<0.0001). Dichotomization of the
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Table I. Calculation of brain metastatic prognostic scores.
RTOG RPA#                                                                                          
CLASS                                                                    I            II            III
KPS                                                                       ≥70        ≥70         <70
                                                                              and        and          and
Age                                                                        <65         all            all
                                                                              and        and          and
Extracranial metastases                                        No     No/Yes    No/Yes
BS-BM*                                                                   
                                                                                 
POINTS                                                                      0                    1
KPS                                                                           ≤70                ≥80
Systemic disease                                                       PD           SD – PR – 
                                                                                                  CR – NED
Extracranial metastases                                            Yes                 No
CERENAL*
                                                                                                           
POINTS                                                                      0                    1
KPS at diagnosis of first brain metastasis              >70                ≤70
Age at diagnosis of first brain metastasis         ≤50 years      >50 years
Progressive disease at diagnosis of first 
brain metastasis (primary tumor included)            No                 Yes
Other extracranial metastasis                                   No                 Yes
Number of brain metastatic lesions                          1                   ≥2
Received stereotactic radiosurgery                         Yes                 No
#Patients are subdivided in class according to the combination of all
three criteria. *Final score is obtained by sum of all individual points.
KPS, Karnofsky performance status.
prognostic scores showed moderate overall percentage
agreement (68%, 79%, 68%) for RTOG RPA versus BS-BM,
CERENAL versus BS-BM, and RTOG RPA versus
CERENAL, respectively. RTOG RPA, BS-BM and CERENAL
showed excellent model fit for first-line PFS (χ2=9.18E-9,
p=0.9999; χ2=6.40E-9, p=1.0000; and χ2=4.57E-9, p=1.0000,
respectively) and OS (χ2=5.74E-9, p=1.0000; χ2=5.74E-9,
p=1.0000; and χ2=7.86E-9, p=1.0000, respectively).
PFS after first- and second-line targeted therapy. A total of
36/75 patients (48%) were diagnosed with brain metastases
at first-line treatment initiation. Median follow-up time since
first-line therapy until death or last follow-up was 54.7
months (42.8-66.5). An overview of administered therapies
with median duration of first-line therapy and PFS per
therapy are given in Table V. 
All prognostic scores showed significance in PFS after
first-line targeted therapy. Patients classified as RTOG RPA
class I/II showed a prolonged PFS in comparison with RTOG
RPA class III [median PFS=10.3 versus 3.6 months;
HR=0.28 (0.02-0.3), p=0.0013]. A similar outcome was
found for the BS-BM score. Having a BS-BM score of 2 or
3 resulted in a 56% reduction in risk of progression
[HR=0.44 (0.17-0.82), p=0.0140] with median PFS of 11.9
months compared with 5.6 months for BS-BM score lower
than 2. Patients having a CERENAL score lower than 4 also
had a longer median PFS (11.9 versus 4.1 months) resulting
in a 64% reduction in risk of progression [HR=0.36 (0.09-
0.57), p=0.0015; Figure 1A-C]. Decision curve analysis for
six-months PFS showed that the CERENAL score achieved
highest net benefit between the 0.2 and 0.4 risk threshold,
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Table II. Clinical characteristics in the intention-to-treat cohort (n=75).
Gender                                                                               
  Male                                                                   57 (76)
  Female                                                               18 (24)
Median age, years                                               55 (28-82)
Histology                                                                          
  Clear-cell                                                           66 (88)
  Papillary                                                              2 (3)
  Chromophobe                                                      2 (3)
  Not determined                                                   5 (7)
Sarcomatoid component                                                   
  Yes                                                                       8 (11)
  No                                                                      28 (37)
  Not determined                                                 39 (52)
Fuhrmann grade                                                               
  I-II                                                                        8 (11)
  III                                                                       27 (36)
  IV                                                                         9 (12)
  Unknown                                                           31 (41)
Nephrectomy                                                                    
  Yes                                                                     57 (76)
  No                                                                      18 (24)
IMDC risk group                                                              
  Good                                                                  12 (16)
  Intermediate                                                      28 (37)
  Poor                                                                   16 (21)
  Unknown                                                           19 (25)
Site of metastasis                                                              
  Lungs                                                                 38 (51)
  Liver                                                                  14 (19)
  Bones                                                                 15 (20)
  Adrenal glands                                                  16 (21)
  Lymph nodes                                                     28 (37)
  Other                                                                  13 (17)
Data given are number (percentage) except for age at RCC diagnosis:
median (range).
Table III. Brain metastases characteristics at brain metastasis diagnosis
in the intention-to-treat cohort (n=75).
Time between diagnosis of primary 
tumor and diagnosis of brain metastasis (months)              15 (0-381)
Brain metastasis at diagnosis                                                      
  Yes                                                                                        15 (20)
  No                                                                                         60 (80)
Other metastatic sites involved 
at brain metastasis diagnosis                                                      
  No sites                                                                                   2 (3)
  Lungs                                                                                    62 (83)
  Lymph nodes                                                                        41 (55)
  Liver                                                                                      17 (23)
  Bones                                                                                    29 (39)
  Adrenal gland                                                                       14 (19)
  Other                                                                                     20 (27)
Localization of brain metastasis                                                 
  Supratentorial                                                                       36 (48)
  Infratentorial                                                                           2 (3)
  Both                                                                                      12 (16)
  Unknown                                                                              25 (33)
Number of brain metastases                                                       
  1                                                                                            38 (51)
  2                                                                                            13 (17)
  3+                                                                                          23 (31)
Not determined                                                                         1 (1)
Neurological symptoms                                                              
  Yes                                                                                        47 (63)
  No                                                                                         28 (37)
Received first-line targeted therapy 
before brain metastasis diagnosis                                               
  Yes                                                                                        39 (52)
  No                                                                                         36 (48)
Additional therapy for brain metastases                                    
  No additional therapy                                                            8 (11)
  WBRT alone                                                                         27 (36)
  SRS alone                                                                             12 (16)
  Surgery + WBRT                                                                 17 (23)
  Surgery + SRS                                                                        3 (4)
  WBRT + SRS                                                                         3 (4)
  Surgery + WBRT + SRS                                                        5 (7)
Data given are number (percentage) except for time between primary
tumor and brain metastasis: median (range). SRS, Stereotactic
radiosurgery; WBRT, whole-brain radiotherapy.
whereas RTOG RPA indicated the highest net benefit above
the 0.4 risk threshold. BS-BM showed the lowest net benefit
for every risk threshold (Figure 2A). A multivariate analysis
proved that the CERENAL score was the sole independent
prognostic factor associated with an improved PFS from
first-line therapy (p=0.0029, Table VI, First-line PFS). 
Twenty-one out of 36 patients diagnosed with brain
metastases at start of first-line therapy together with 8
patients newly diagnosed with brain metastases during their
first-line therapy received second-line targeted therapy. An
overview of administered therapies and median duration of
second-line therapy are given in Table V.
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Table IV. Brain metastasis prognostic scores at brain metastasis diagnosis in the intention-to-treat cohort (n=75).
Prognostic scores                   n                     (%)                      mOS (95%CI)                    p-Value                       mDSS (95%CI)                      p-Value
RTOG RPA                                                                                                                                                                                                                  
  I                                             1                      (1)                       35.6 (–)                                0.0001                      35.6 (–)                                     0.0007
  II                                         49                    (65)                      19.3 (10.2-30.5)                                                    16.8 (10.2-32.5)                         
  III                                        25                    (33)                        6.0 (3.4-9.1)                                                          6.0 (2.6-11.5)                           
BS-BM                                                                                                                                                                                                                         
  0                                          13                    (17)                        5.6 (2.2-10.5)                    0.0001                        5.6 (1.0-12.2)                         0.0015
  1                                          36                    (48)                        9.1 (5.0-14.9)                                                      10.2 (5.0-15.2)                           
  2                                          25                    (33)                      30.5 (19.3-40.6)                                                    22.6 (14.2-67.6)                         
  3                                            1                      (1)                       35.6 (–)                                                                  35.6 (–)                                       
CERENAL                                                                                                                                                                                                                   
  1                                            2                      (3)                       58.9 (–)                              <0.0001                      35.6 (–)                                  <0.0001
  2                                          11                    (15)                      39.3 (30.5-70.5)                                                    67.6 (32.5-70.6)                         
  3                                          16                    (21)                      19.3 (9.2-22.6)                                                      19.3 (9.2-23.8)                           
  4                                          21                    (28)                        6.3 (5.0-13.2)                                                        6.3 (3.1-13.2)                           
  5                                          21                    (28)                      10.9 (4.4-15.2)                                                      11.5 (4.7-15.2)                           
  6                                            4                      (5)                         1.0 (1.0-10.5)                                                        1.0 (1.0-2.3)                             
Data given are number (percentage). mOS and mDSS are given in months. 95%CI, 95% Confidence interval; BS-BM, basic score for brain
metastases; mDSS, median disease-specific survival; mOS, median overall survival; RTOG RPA, radiation therapy oncology group recursive
partitioning analysis.
Table V. Targeted therapies administered in patients diagnosed with brain metastasis and survival outcome.
Therapy                                                                        n                    (%)                  mPFS (95%CI)                mOS (95%CI)                 mDSS (95%CI)
Intention-to-treat cohort*                                          75                   (100)                  10.1 (7.1-11.4)               11.5 (8.8-16.8)                 12.2 (8.5-16.8)
First-line therapy§                                                     36                   (100)                  10.1 (4.1-11.9)               16.8 (12.2-32.9)               15.2 (11.5-39.3)
   Sunitinib                                                                 21                    (58)                   10.3 (7.8-14.2)               20.4 (4.2-67.6)                 16.8 (12.2-70.5)
   Pazopanib                                                                 3                     (8)                      2.6 (2.6-3.6)                 10.5 (3.9-13.9)                 13.9 (–)
   Sorafenib                                                                  5                    (14)                   11.2 (10.1-11.9)             39.3 (19.3-58.9)               22.3 (19.3-40.6)
   Everolimus                                                                2                     (6)                      2.6 (2.6-5.6)                 10.9 (10.9-11.5)               10.9 (10.9-11.5)
   Temsirolimus                                                            5                    (14)                     2.2 (1.0-23.4)                 6.0 (2.3-23.8)                   6.0 (2.3-23.8)
Duration first-line therapy (months)                          9.6           (1.0-55.8)                                                                                                   
Number of patients stopped for AE                           5                    (14)                                                                                                        
Second-line therapy+                                                29                   (100)                    5.0 (3.1-6.5)                 32.5 (15.2-52.7)               23.8 (14.9-40.6)
   Sunitinib                                                                   4                    (14)                     5.1 (0.4-19.7)               39.3 (23.8-58.9)               39.3 (23.8-40.6)
   Pazopanib                                                                 1                     (3)                      2.6 (–)                          13.9 (–)                             13.9 (–)
   Sorafenib                                                                  5                    (17)                     2.8 (1.4-5.0)                 11.5 (10.9-70.6)               11.5 (10.9-70.6)
   Everolimus                                                             12                    (41)                     4.1 (2.1-37.5)               32.5 (16.8-54.0)               22.4 (14.9-54.0)
   Axitinib                                                                     4                    (14)                     3.5 (3.1-6.5)                 10.5 (8.5-15.2)                 15.2 (8.5-NR)
   Temsirolimus                                                            2                     (7)                      7.0 (–)                          70.5 (70.5-70.6)               70.5 (70.5-70.6)
   Interferon-γ                                                               1                     (3)                      5.1 (–)                            8.8 (–)                               8.8 (–)
Duration second-line therapy (months)                     3.5           (0.0-37.5)                                                                                                   
Number of patients stopped for AE                           6                    (21)                                                                                                        
Data given are number (percentage) except for duration of therapy: median (range). mPFS, mOS and mDSS are given in months. *mPFS in intention-
to-treat cohort is independent of prior targeted therapy before brain metastasis diagnosis. §A total of 36 patients were diagnosed with brain metastases
before first-line therapy was initiated. +Out of the 36 patients with brain metastases who were treated in first-line, 21 started second-line therapy
together with eight patients diagnosed with brain metastases during first-line therapy. 95%CI, 95% Confidence interval; mDSS, median disease-
specific survival; mOS, median overall survival; mPFS, median progression-free survival.
In comparison to first-line therapy, no prognostic value
was found for RTOG RPA [HRRTOG RPA class I/II=0.62 (0.18-
1.66)], BS-BM [HRBS-BM 2-3=0.65 (0.26-1.46)] or
CERENAL [HRCERENAL 1-3=0.76 (0.33-1.75)]. This is also
shown on the decision curves for six-months PFS with only
marginal net benefit found for CERENAL between the 0.55
and 0.75 risk threshold (Figure 2B).
OS and DSS. Of all patients, 63/75 (84%) were deceased and
9/75 (12%) were lost-to-follow-up at time of OS analysis.
Median follow-up time since diagnosis of brain metastases until
death or last follow-up was 62.1 months (52.6-71.5). Median
OS per first- and second-line therapy are given in Table V.
Univariate analysis confirmed the prognostic value of the
different prognostic scores. Patients classified as RTOG RPA
class I/II showed a median OS of 20.4 versus 6.0 months for
patients classified as RTOG RPA class III [HR=0.36 (0.11-
0.44), p<0.0001]. Moreover, patients with BS-BM 2-3 had an
improved outcome compared with patients with BS-BM 0-1
[median OS=30.5 versus 6.6 months; HR=0.38 (0.17-0.55),
p<0.0001]. Median OS was significantly longer in patients
with CERENAL 1-3 versus CERENAL 4-6 (30.5 versus 6.3
months) with a 59% reduction in risk of death [HR=0.37 (0.17-
0.51), p<0.0001] (Figure 3A-C). Patients receiving local
therapy for brain metastases had an improved median OS
versus those who did not [13.9 versus 5.3 months; HR=0.44
(0.09-0.90), p=0.0324]. Highest net benefit for six-months OS
was found for CERENAL for risk thresholds up to 0.4 whereas
RTOG RPA proved more beneficial between the 0.4 and 0.5
risk threshold (Figure 2C). At one-year OS, BS-BM and
CERENAL proved to be comparable on decision curve
analysis with highest net benefit between the 0.3 and 0.55 risk
threshold, although RTOG RPA is more beneficial between the
0.55 and 0.8 risk threshold (Figure 2D). This was deflected in
the multivariate analysis which suggested that RTOG RPA
(p=0.0428) and CERENAL score (p=0.0063) are independent
prognostic factors (Table VI, OS).
Of all deceased patients, 49/63 (78%) died from their
disease. Comparable to OS, all prognostic scores were
significant for DSS. Median DSS for first- and second-line
therapy are given in Table V. Having a prognostic favorable
score resulted in a significant reduction in risk of death of
63%, 61% and 62% for RTOG RPA, BS-BM and CERENAL,
respectively (p=0.0002, p=0.0007 and p=0.0003; Figure 4A-
C). Likewise, patients who had additional brain metastatic
therapy lived longer in comparison to patients who did not
undergo local therapy [13.9 vs. 5.0 months; HR=0.42(0.08-
0.94), p=0.0390]. Decision curves for six-months DSS and
one-year DSS were similar with those observed for six-
months OS and one-year OS (Figure 2E and F). However, in
contrast to OS, only CERENAL (p=0.0005) was an
independent prognostic factor associated with DSS in the
multivariate analysis (Table VI, DSS).
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Figure 1. Kaplan-Meier first-line progression-free survival curves for
brain metastasis prognostic scores. Y-axis depicts cumulative survival
(%), X-axis depicts survival time in months. Survival curves are
demonstrated for (A) RTOG RPA (p=0.0013), (B) BS-BM (p=0.0140),
(C) CERENAL (p=0.0015). BS-BM, Basic score for brain metastases;
PFS, progression-free survival; RTOG RPA, radiation therapy oncology
group recursive partitioning analysis.
Discussion
Patients with RCC diagnosed with brain metastases have a poor
survival. Several brain metastatic prognostic scores have been
reported in the literature over the last decade. Data in a
metastatic RCC setting are, however, scanty. We, therefore,
retrospectively determined the prognostic value of several
prognostic scores, developed for brain metastases in solid
tumors, in a cohort of 75 patients with brain metastatic RCC
receiving targeted agents (tyrosine kinase inhibitors or mTOR
inhibitors). Here, we evaluated two already described prognostic
scores, RTOG RPA and BS-BM (10, 11), as well as a de novo
composed score CERENAL.
In our study population, 75% of patients were diagnosed
with metastatic disease at primary RCC diagnosis which is
considerable higher compared to other reported data (4). This
could be explained by the fact that the brain is rarely the
only metastatic site in RCC. Nearly 20% of our patients
presented with brain metastases at primary tumor diagnosis.
This is comparable to the extent registered in other RCC
studies (7-26.8%). It is notable that the time from primary
RCC diagnosis to diagnosis of brain metastases is clearly
shorter in our study (15 months) (15, 16).
In addition to the previously described prognostic scores
RTOG RPA and BS-BM, we assessed the novel score named
CERENAL in which points were attributed according to risk
factors described in RTOG RPA and BS-BM. Furthermore,
the number of brain metastatic lesions was also included in
the CERENAL score since Ferrel et al. (13) reported an
improved OS in RCC patients with a low number of
intracranial metastases. Since SRS therapy has been shown
to have a positive effect on the survival outcome of brain
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Figure 2. Decision curve analysis for brain metastasis prognostic scores. Y-axis depicts the standardized net benefit, X-axis depicts the risk
thresholds. Decision curves (RTOG RPA=blue line, BS-BM=red line, CERENAL=green line) are demonstrated for (A) six-months first-line PFS,
(B) six-months second-line PFS, (C) six-months OS, (D) one-year OS, (E) six-months DSS, (F) one-year DSS. BS-BM, Basic score for brain
metastases; PFS, progression-free survival; RTOG RPA, radiation therapy oncology group recursive partitioning analysis.
metastatic RCC patients (8), it was decided to include SRS
in the CERENAL score. However, several trials have reported
no difference in outcome between SRS and local therapies for
brain metastases (17-20). Due to the fact that several mutual
risk factors were used, all prognostic scores were comparable
to each other with the highest level of agreement noticed
between CERENAL and BS-BM. In addition, we confirmed
the robustness of all prognostic scores used in our study.
In the present study, median OS was between 11.5 months
(intention-to-treat group) and 16.8 months (brain metastases
before first-line targeted therapy) which is similar to the
survival data from other studies in RCC patients with brain
metastases (9, 15, 16, 21). Compared to the OS data from large
phase III trials, in which patients with brain metastatic disease
were excluded, OS is significantly shorter (22-30). This
difference, however, was not the result of a possible decrease
in first-line PFS. Median first-line PFS was 10.1 months with
the majority of patients receiving sunitinib as first-line therapy.
This is only marginally shorter than the survival data from
previously reported phase III trials COMPARZ and RECORD-
3 (25, 29), suggesting that having brain metastases seems to
have only little to no impact on first-line PFS. This has already
been hypothesized by Kusuda et al. (31) who reported that
sunitinib might harbor some effect on brain metastases. Next,
second-line PFS was only 5.0 months which is in accordance
with second-line PFS in large phase III trials (AXIS,
RECORD-1) with tyrosine kinase inhibitors (23, 25, 28, 30)
and the mTOR inhibitor everolimus (27).
Based on these data it is clear that RCC patients with
brain metastases have a poor prognosis. Use of brain
metastatic prognostic scores in these patients can, therefore,
be useful to determine which patients would benefit from
prolonged therapy. It has been previously described for
melanoma, lung and breast cancer that the RTOG RPA and
the BS-BM result in significantly different survival curves
(19, 32-34). To our knowledge, such an extensive survival
comparison has not yet been made for brain metastatic RCC. 
RTOG RPA and BS-BM developed in other malignancies
were significantly associated in our study with both OS and
DSS. Moreover, our newly constructed CERENAL score was
also able to distinguish patients with good prognosis from those
with poor prognosis at the predefined cut-off value. Thus, any
type of local therapy for brain metastases significantly prolonged
OS and DSS. Consequent multivariate analysis revealed RTOG
RPA and CERENAL as independent prognostic factors for OS
but only CERENAL was associated with survival benefit for
DSS with a 70% reduction in risk of death for CERENAL scores
lower than 4. Besides, all prognostic scores were also useful
during first-line therapy. Multivariate analysis, however, showed
that only having a CERENAL score lower than 4 was associated
with a 72% risk of progression compared to patients with a
CERENAL score equal to or higher than 4. This was also clearly
depicted in the decision curve analyses for first-line PFS, OS and
DSS. It was clearly noted that CERENAL achieved higher net
benefits at lower risk thresholds, whereas RTOG RPA was more
beneficial at higher risk thresholds. This could indicate that
CERENAL could be helpful as a prognostic tool and that the
combination with RTOG RPA could lead to the highest net
benefit for this patient population. None of the prognostic scores
showed significance for second-line therapy.
Our study however has some limitations, especially due to
its retrospective nature. Firstly, the presence of brain metastases
in RCC is rare. Therefore, the study population is rather
heterogeneous and does not allow us to draw hard conclusions.
Secondly, due to its retrospective character, it is difficult to
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Table VI. Multivariate survival analysis.
Parameter                                                      HR (95%CI)           p-Value
First-line PFS
RTOG RPA                                                                                         
 I/II                                                                         1                           
 III                                                              2.76 (0.83-9.22)         0.0989
BS-BM                                                                                                
 0-1                                                                         1                           
 2-3                                                            0.86 (0.23-3.15)         0.8186
CERENAL                                                                                         
 1-3                                                                         1                           
 4-6                                                            3.59 (1.55-8.34)         0.0029
OS
RTOG RPA                                                                                         
 I/II                                                                         1                           
 III                                                              1.95 (1.02-3.72)         0.0428
BS-BM                                                                                                
 0-1                                                                         1                           
 2-3                                                            0.65 (0.21-1.98)         0.4479
CERENAL                                                                                         
 1-3                                                                         1                           
 4-6                                                            2.56 (1.30-5.03)         0.0063
Local therapy for brain metastases                                                   
 No                                                                         1                           
 Yes                                                            0.78 (0.34-1.79)         0.5575
DSS
RTOG RPA                                                                                         
 I/II                                                                         1                           
 III                                                              1.90 (0.93-3.87)         0.0785
BS-BM                                                                                                
 0-1                                                                         1                           
 2-3                                                            0.66 (0.19-2.32)         0.5174
CERENAL                                                                                         
 1-3                                                                         1                           
 4-6                                                            3.34 (1.70-6.56)         0.0005
Local therapy for brain metastases                                                   
 No                                                                         1                           
 Yes                                                            0.67 (0.27-1.66)         0.6698
Multivariate HRs were calculated via a Cox proportional-hazards
regression model. 95%CI, 95% Confidence interval; BS-BM, basic
score for brain metastases; DSS, disease-specific survival; OS, overall
survival; PFS, progression-free survival; RTOG RPA, radiation therapy
oncology group recursive partitioning analysis.
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Figure 4. Kaplan–Meier disease-specific survival curves for brain
metastasis prognostic scores. Y-axis depicts cumulative survival (%), 
X-axis depicts survival time in months. Survival curves are demonstrated
for (A) RTOG RPA (p=0.0002), (B) BS-BM (p=0.0007), (C) CERENAL
(p=0.003). BS-BM, Basic score for brain metastases; DSS, disease-
specific survival; RTOG RPA, radiation therapy oncology group
recursive partitioning analysis.
Figure 3. Kaplan–Meier overall survival curves for brain metastasis
prognostic scores. Y-axis depicts cumulative survival (%), X-axis
depicts survival time in months. Survival curves are demonstrated for
(A) RTOG RPA (p<0.0001), (B) BS-BM (p<0.0001), (C) CERENAL
(p<0.0001). BS-BM, Basic score for brain metastases; OS, overall
survival; RTOG RPA, radiation therapy oncology group recursive
partitioning analysis.
implement decision curve analysis for PFS and OS due to the
high number of patients already progressed and deceased,
respectively. Thirdly, insufficient data were present in the patient
files to determine the prognostic effect of the MSKCC or Heng
criteria in our study population. It would be of great interest to
determine the added value of the proposed brain metastatic
prognostic marker CERENAL value over the already validated
prognostic criteria known in RCC. Nevertheless, our
retrospective study has shown some interesting findings which
can guide future prognostic research in RCC patients diagnosed
with brain metastases. Further validation in prospectively
enrolled RCC cohorts is, therefore, needed to fully evaluate the
prognostic value of the CERENAL score.
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